Breast international group (BIG) – aisbl
Rue de bretagne 20,
1200 Brussels, Belgium
VAT BE 0468 176 240
IBAN BE08 0689 0916 0213
Navigation
The Breast International Group is proud to adhere
to the Code of Ethics of the VEF-AERF
Trials and programmes
Research saves lives
Status
Settings
Subtypes
Status
Settings
Subtypes
Others
Search
SOFT / TEXT
BIG 2-02 / BIG 3-02
Testing different post-operative endocrine treatments for young women with hormone-sensitive breast cancer
SNAP
BIG 2-12
Evaluation of different schedules of nab-paclitaxel for metastatic breast cancer
DCIS
BIG 3-07
A randomized phase III study of radiation doses and fractionation schedules in non-low risk Ductal Carcinoma In Situ (DCIS) of the breast
PANACEA
BIG 4-13
anti-PD-1 monoclonAl aNtibody in AdvanCed, trastuzumab-resistant, HER2-positive breAst cancer
DECRESCENDO
BIG 19-02
De-escalation of adjuvant chemotherapy in HER2-positive, HR-negative breast cancer
AMEERA-6
BIG 20-01
Amcenestrant in patients with HR+, HER2-negative/positive breast cancer who experienced toxicities with aromatase inhibitors
BIG 1-98 / IBCSG 18-98
BIG 1-98
Letrozole or tamoxifen in treating postmenopausal women with breast cancer
ULTIMATE
BIG 16-01
Immunotherapy as neoadjuvant treatment in ER+/HER2-negative breast cancer
TREAT CTC
BIG 1-12
TRastuzumab treatment for HER2-negative early breast cancer in the presence of circulating tumor cells
SOFT / TEXT
BIG 2-02 / BIG 3-02
Testing different post-operative endocrine treatments for young women with hormone-sensitive breast cancer
SNAP
BIG 2-12
Evaluation of different schedules of nab-paclitaxel for metastatic breast cancer
LORELEI
BIG 3-13
Different regimes of letrozole (or letrozole + taselisib) in postmenopausal women with ER positive/HER2-negative, early stage breast cancer
BRAVO
BIG 5-13
Niraparib for patients with HER2-negative, germline BRCA mutation-positive breast cancer
SOLE
BIG 1-07
ontinuous versus intermittent letrozole following endocrine treatment for postmenopausal women with disease-free of hormone-receptor positive, node-positive early stage breast cancer
PENELOPE-B
BIG 1-13
Post-neoadjuvant palbociblib for patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk
PYTHIA
BIG 14-04
Palbociclib in molecularly characterised ER-positive/HER2-negative metastatic breast cancer
MA.32 Metformin
BIG 5-11
Effect of metformin on recurrence and survival in early stage breast cancer
OlympiA
BIG 6-13
Olaparib as adjuvant treatment in patients with germline BRCA-mutated high risk HER2 negative primary breast cancer (OlympiA)
POLAR
BIG 18-02
Palbociclib for HR+ isolated local or regional recurrence of breast cancer
Male Breast Cancer
BIG 2-07
Clinical and Biological Characterization of Male Breast Cancer
Exceptional Responders
BIG 16-04
A global hunt for Exceptional Responders in the BIG network
Breast Cancer in Pregnancy
BIG 2-03
Prospective Register Study for Diagnosis and Treatment of Breast Cancer in Pregnancy
NeoALTTO
BIG 1-06
Comparison of dual HER2 inhibition (lapatinib, trastuzumab) plus chemotherapy before surgery versus single HER2-targeted therapy
MINDACT
BIG 3-04
Can addition of 70-gene signature to common clinical-pathological criteria safely spare patients from adjuvant chemotherapy?
HERA
BIG 1-01
Comparison of different regimes of trastuzumab for women with HER2-positive primary breast cancer
EXPERT
BIG 16-02
EXamining PErsonalised Radiation Therapy for low-risk early breast cancer
DCIS
BIG 3-07
A randomized phase III study of radiation doses and fractionation schedules in non-low risk Ductal Carcinoma In Situ (DCIS) of the breast
POSITIVE
BIG 8-13
Endocrine therapy interruption to enable conception for young women with ER+ breast cancer
AURORA
BIG 14-01
Aiming to understand the molecular aberrations in metastatic breast cancer
APHINITY
BIG 4-11
Comparison of single-versus-dual anti-HER2 therapy (trastuzumab, pertuzumab) for patients with HER2-positive primary breast cancer
ALTTO
BIG 2-06
Adjuvant lapatinib and trastuzumab: sequence and combination for patients with HER2/ErbB2 positive primary breast cancer
ALEXANDRA IMpassion030
BIG 16-05
Comparison of adjuvant anti PD-L1 antibody (atezolizumab) plus chemotherapy versus chemotherapy alone in TNBC patients